Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.

Leukemia Research
Zhen GuoXiao-Dong Lyu

Abstract

Tet methylcytosine dioxygenase 2 (TET2) mutations occur frequently in myelodysplastic syndromes (MDS), but its prognostic impact has not been fully assessed and was controversial. Therefore, we performed a meta-analysis to evaluate the prognostic significance of TET2 mutations in MDS. PubMed, EMBASE databases and Cochrane Library were searched for studies reporting TET2 mutations and overall survival in MDS. Hazard ratios (HR) with 95% confidence interval (CI) were determined using random-effect modeling. A total of 1494 patients from nine studies were subjected to meta-analysis. The frequency of TET2 mutations was 18.34% (274/1494) in the study. MDS with TET2 mutations had similar overall survival compared to patients without the mutations (hazard ratio 1.13, 95% CI: 0.81-1.5).Our findings suggest that TET2 mutations have no prognosis impact on OS of patients with MDS. Therefore, the status of TET2 mutations cannot be served as a prognostic marker in MDS.

Citations

Mar 15, 2019·Journal of Internal Medicine·M Tobiasson, A O Kittang
Jun 13, 2019·Molecular Genetics & Genomic Medicine·Elena BussagliaPablo Fuentes-Prior
Oct 2, 2019·British Journal of Haematology·Travis P SpauldingMichael R Savona
Nov 25, 2019·Current Hematologic Malignancy Reports·David M Swoboda, David A Sallman
Apr 20, 2019·Frontiers in Oncology·Yimei FengXi Zhang
Jun 3, 2021·Journal of Clinical Medicine·Tzu-Hua Chen-Liang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.